Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment

OncoImmunology

Volumn 5, Issue 2, 2016, Pages

  Fend, Laetitia ^a,b   Remy Ziller, Christelle ^a,b   Foloppe, Johann ^a,b   Kempf, Juliette ^a,b   Cochin, Sandrine ^a,b   Barraud, Luc ^a,b   Accart, Nathalie ^c   Erbs, Philippe ^a,b   Fournel, Sylvie ^d   Préville, Xavier ^a,b  

^a TRANSGENE S A   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Faculté de Pharmacie   (France)

Author keywords

Oncolytic virotherapy; regulatory T cells; renal carcinoma; suicide gene therapy; tumor microenvironment; vaccinia virus

Indexed keywords

EID: 84959423031     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1080414     Document Type: Article

References (27)

1. S.J.Russell, K.-W.Peng, J.C.Bell. Oncolytic virotherapy. Nat Biotech 2012; 30:658-70; PMID:22781695; http://dx.doi.org/10.1038/nbt.2287
2. J.Heo, T.Reid, L.Ruo, C.J.Breitbach, S.Rose, M.Bloomston, M.Cho, H.Y.Lim, H.C.Chung, C.W.Kim et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19:329-36; PMID:23396206; http://dx.doi.org/10.1038/nm.3089
3. B.Acres, K.Dott, L.Stefani, M.P.Kieny. Directed cytokine expression in tumour cells in vivo using recombinant vaccinia virus. Ther Immunol 1994; 1:17-23; PMID:7584475
4. P.Erbs, E.Regulier, J.Kintz, P.Leroy, Y.Poitevin, F.Exinger, R.Jund, M.Mehtali. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60:3813-22; PMID:10919655
5. J.Foloppe, J.Kintz, N.Futin, A.Findeli, P.Cordier, Y.Schlesinger, C.Hoffmann, C.Tosch, J.M.Balloul, P.Erbs. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008; 15:1361-71; PMID:18480846; http://dx.doi.org/10.1038/gt.2008.82
6. P.Huang, H.Kaku, J.Chen, Y.Kashiwakura, T.Saika, Y.Nasu, Y.Urata, T.Fujiwara, M.Watanabe, H.Kumon. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma. Cancer Gene Ther 2010; 17:484-91; PMID:20168351; http://dx.doi.org/10.1038/cgt.2010.5
7. L.A.Norian, T.P.Kresowik, H.M.Rosevear, B.R.James, T.R.Rosean, A.J.Lightfoot, T.A.Kucaba, C.Schwarz, C.J.Weydert, M.D.Henry et al. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One 2012; 7:e31085; PMID:22312440; http://dx.doi.org/10.1371/journal.pone.0031085
8. B.Ljungberg, S.C.Campbell, H.Y.Cho, D.Jacqmin, J.E.Lee, S.Weikert, L.A.Kiemeney. The epidemiology of renal cell carcinoma. Eur Urol 2011; 60:615-21; PMID:21741761; http://dx.doi.org/10.1016/j.eururo.2011.06.049
9. B.Bockorny, C.A.Dasanu. Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther 2013; 13:911-25; PMID:23586712; http://dx.doi.org/10.1517/14712598.2013.778970
10. F.Ghiringhelli, L.Apetoh, A.Tesniere, L.Aymeric, Y.Ma, C.Ortiz, K.Vermaelen, T.Panaretakis, G.Mignot, E.Ullrich et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028
11. L.Apetoh, F.Ghiringhelli, A.Tesniere, M.Obeid, C.Ortiz, A.Criollo, G.Mignot, M.C.Maiuri, E.Ullrich, P.Saulnier et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622
12. I.Martins, A.Tesniere, O.Kepp, M.Michaud, F.Schlemmer, L.Senovilla, C.Seror, D.Metivier, J.L.Perfettini, L.Zitvogel et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8:3723-8; PMID:19855167; http://dx.doi.org/10.4161/cc.8.22.10026
13. N.Bercovici, A.Trautmann. Revisiting the role of T cells in tumor regression. Oncoimmunology 2012; 1:346-50; PMID:22737611; http://dx.doi.org/10.4161/onci.18800
14. S.K.Biswas, A.Mantovani. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11:889-96; PMID:20856220; http://dx.doi.org/10.1038/ni.1937
15. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
16. Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y, 710 Kroemer G. STAT3 inhibition enhances the therapeutic efficacy of immunogenic chemotherapy by stimulating type 1 interferon production by cancer cells. Cancer Res 2015; 75:3812-22; PMID:26208907; http://dx.doi.org/10.1158/0008-5472.CAN-15-1122
17. L.B.John, L.J.Howland, J.K.Flynn, A.C.West, C.Devaud, C.P.Duong, T.J.Stewart, J.A.Westwood, Z.S.Guo, D.L.Bartlett et al. Oncolytic virus and anti–4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 2012; 72:1651-60; PMID:22315352; http://dx.doi.org/10.1158/0008-5472.CAN-11-2788
18. J.Vincent, G.Mignot, F.Chalmin, S.Ladoire, M.Bruchard, A.Chevriaux, F.Martin, L.Apetoh, C.Rebe, F.Ghiringhelli. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70:3052-61; PMID:20388795; http://dx.doi.org/10.1158/0008-5472.CAN-09-3690
19. C.Fayolle, U.M.Abdel-Motal, L.Berg, E.Deriaud, M.Jondal, C.Leclerc. Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help. Immunology 1996; 89:41-5; PMID:8911138; http://dx.doi.org/10.1046/j.1365-2567.1996.d01-704.x
20. S.P.Schoenberger, R.E.Toes, E.I.van der Voort, R.Offringa, C.J.Melief. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393:480-3; PMID:9624005; http://dx.doi.org/10.1038/31002
21. R.R.Salup, R.B.Herberman, R.H.Wiltrout. Role of natural killer activity in development of spontaneous metastases in murine renal cancer. J Urol 1985; 134:1236-41; PMID:4057425
22. T.F.Gajewski, S.-R.Woo, Y.Zha, R.Spaapen, Y.Zheng, L.Corrales, S.Spranger. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013; 25:268-76; PMID:23579075; http://dx.doi.org/10.1016/j.coi.2013.02.009
23. W.H.Fridman, F.Pagès, C.Sautès-Fridman, J.Galon. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
24. H.D.Hickman, G.V.Reynoso, B.F.Ngudiankama, S.S.Cush, J.Gibbs, J.R.Bennink, J.W.Yewdell. CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells. Immunity 2015; 42:524-37; PMID:25769612; http://dx.doi.org/10.1016/j.immuni.2015.02.009
25. P.Erbs, A.Findeli, J.Kintz, P.Cordier, C.Hoffmann, M.Geist, J.M.Balloul. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther 2008; 15:18-28; PMID:17992203; http://dx.doi.org/10.1038/sj.cgt.7701098
26. J.M.Wigginton, K.L.Komschlies, T.C.Back, J.L.Franco, M.J.Brunda, R.H.Wiltrout. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996; 88:38-43; PMID:8847724; http://dx.doi.org/10.1093/jnci/88.1.38
27. J.H.Beckstead. A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. J Histochem Cytochem: Off J Histochem Soc 1994; 42:1127-34; PMID:8027531; http://dx.doi.org/10.1177/42.8.8027531